Uganda has approved the long-lasting injectable HIV drug Cabotegravir, becoming the second African country to do so after Zimbabwe. The PrEP, or pre-exposure prophylaxis, treatment prevents the transmission of the virus. About 1.4 million people are living with HIV in Uganda, according to official data. Africa 54 health correspondent Linord Moudou spoke with Nelson Musoba, executive director of Uganda AIDS Commission, who cautioned against complacency, especially among young people.